Göksel GÜVEN, Rahmi YILMAZ, Tolga YILDIRIM, Fazıl Tuncay AKI, Yunus ERDEM

Underlying Causes and Risk Factors of Chronic Renal Allograft Dysfunction Among Renal Transplant Recipients

Objective: Dialysis or renal transplantation are the two treatment options for end-stage renal disease patients. Renal transplantation from an appropriate donor increases survival and quality of life compared to treatment with dialysis. Recent advances in immunosuppressive therapy have significantly improved the success in 1-year graft survival. However, the long-term graft survival remains the same. Therefore, we aimed to determine the underlying causes and risk factors of chronic allograft dysfunction in renal transplant recipients. Materials and Methods: From 2000 to 2012, all consecutive renal transplant recipients followed in our tertiary referral center who underwent renal biopsy due to an increase in serum creatinine level were enrolled. Etiologies of chronic allograft dysfunction were assessed according to pathologic results of renal biopsy specimens and laboratory findings. The immunological and non-immunological risk factors of chronic allograft dysfunction were screened and recorded retrospectively. Results: Eighty (80) renal transplant recipients with a mean age of 38±10 years were included in the study. Delayed graft function (p=0.007), history of acute rejection (p

PDF

___

[1] Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2020; 395(10225): 709–33.

[2] Seyahi N, Ates K, Suleymanlar G. Current Status of Renal Replacement Therapy in Turkey: A Summary of the Turkish Society of Nephrology Registry Report. Turk J Nephrol. 2020; 29(1): 6–11.

[3] Quiroga I, McShane P, Koo DDH, et al. Major effects of delayed graft function and cold ischaemia time on renal allograft survival. Nephrol Dial Transplant. 2006; 21(6): 1689–96.

[4] Queeley GL, Campbell ES. Comparing treatment modalities for end-stage renal disease: a meta-analysis. Value Health. 2014; 17(3): A290.

[5] Woo YMUN, Gill JS, Johnson N, et al. The advanced age deceased kidney donor: Current outcomes and future opportunities. Kidney Int. 2005; 67(6): 2407–14.

[6] Shrestha B, Haylor J, Raftery A. Historical Perspectives in Kidney Transplantation: An Updated Review. Prog Transplant. 2015; 25(1): 64–76.Hariharan S, Mcintosh MJ. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000; 8.

[7] Meier-Kriesche H-U, Ojo AO, Hanson JA, et al. Increased impact of acute rejection of acute rejection on chronic allograft failure in recent era: Transplantation. 2000; 70(7): 1098–100.

[8] McDonald S, Russ G, Campbell S, et al. Kidney Transplant Rejection in Australia and New Zealand: Relationships Between Rejection and Graft Outcome. Am J Transplant. 2007; 7(5): 1201–8.

[9] Pascual M, Theruvath T, Kawai T, et al. Strategies to Improve Long-Term Outcomes after Renal Transplantation. N Engl J Med. 2002; 346(8): 580–90.

[10] Ahmad I. Biopsy of the Transplanted Kidney. Semin Interv Radiol. 2005; 21(04): 275–81.

[11] Ponticelli CE. The impact of cold ischemia time on renal transplant outcome. Kidney Int. 2015; 87(2): 272–5.

[12] Piazza A, Poggi E, Borrelli L, et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: Posttransplant analysis using flow cytometric techniques. Transplantation. 2001;71(8): 1106–12.

[13] Mao Q, Terasaki PI, Cai J, et al. Extremely High Association Between Appearance of HLA Antibodies and Failure of Kidney Grafts in a Five-Year Longitudinal Study. Am J Transplant. 2007; 7(4): 864–71.

[14] Lachmann N, Terasaki PI, Budde K, et al. Anti-Human Leukocyte Antigen and Donor-Specific Antibodies Detected by Luminex Posttransplant Serve as Biomarkers for Chronic Rejection of Renal Allografts: Transplantation. 2009; 87(10): 1505–13.

[15] Lee P-C, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies: Transplantation. 2002; 74(8): 1192–4.

[16] Knoll G. Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation. Can Med Assoc J. 2005; 173(10): S1–25.

[17] Mathis AS, Egloff G, Ghin HL. Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies. World J Transplant. 2014; 4(2): 57.

[18] Panek R, Tennankore KK, Kiberd BA. Incidence, etiology, and significance of acute kidney injury in the early postkidney transplant period. Clin Transplant. 2016; 30(1): 66–70.

[19] Sawinski D, Trofe-Clark J, Leas B, et al. Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis. Am J Transplant. 2016; 16(7): 2117–38.

[20] Nankivell BJ, Borrows RJ, Fung CL-S, et al. Natural History, Risk Factors, and Impact of Subclinical Rejection in Kidney Transplantation. Transplant J. 2004; 78(2): 242–9.

[21] Briganti EM, Russ GR, McNeil JJ, et al. Risk of Renal Allograft Loss from Recurrent Glomerulonephritis. N Engl J Med. 2002; 347(2): 103–9.

[22] Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis. 2004; 43(6): 1071–81.

[23] Barraclough KA, Isbel NM, Staatz CE, Johnson DW. BK Virus in Kidney Transplant Recipients: The Influence of Immunosuppression. J Transplant. 2011; 1–9.

[24] Lee S, Lee KW, Kim SJ, et al. Clinical Characteristic and Outcomes of BK Virus Infection in Kidney Transplant Recipients Managed Using a Systematic Surveillance and Treatment Strategy. Transplant Proc. 2020; 52(6): 1749–56.